Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2005-02-22
2005-02-22
Achutamurthy, Ponnathapura (Department: 1652)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S069100, C435S226000, C435S252300
Reexamination Certificate
active
06858402
ABSTRACT:
The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amount sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.
REFERENCES:
patent: 4340586 (1982-07-01), Bekierkunst et al.
patent: 4695590 (1987-09-01), Lippman
patent: 4959353 (1990-09-01), Brown et al.
patent: 4983586 (1991-01-01), Bodor
patent: 5002935 (1991-03-01), Bodor
patent: 5017566 (1991-05-01), Bodor
patent: 5130298 (1992-07-01), Cini et al.
patent: 5140043 (1992-08-01), Darr et al.
patent: 5153179 (1992-10-01), Eibl
patent: 5192537 (1993-03-01), Osband
patent: 5268384 (1993-12-01), Galardy
patent: 5270326 (1993-12-01), Galardy et al.
patent: 5376682 (1994-12-01), Naiki et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5643740 (1997-07-01), Billing et al.
patent: 5665859 (1997-09-01), Wallach et al.
patent: 5736356 (1998-04-01), Sano et al.
patent: 5766917 (1998-06-01), Wallach et al.
patent: 6232446 (2001-05-01), Wallach et al.
patent: 6569664 (2003-05-01), Gatanaga et al.
patent: 6573062 (2003-06-01), Gatanaga et al.
patent: 211 077 (1993-05-01), None
patent: 568 925 (1993-11-01), None
patent: 623 676 (1994-11-01), None
patent: 657 536 (1995-06-01), None
patent: 418 014 (1995-12-01), None
patent: WO 9011287 (1990-10-01), None
patent: WO 9014363 (1990-11-01), None
patent: WO 9104014 (1991-04-01), None
patent: WO 9307286 (1993-04-01), None
patent: WO 9320186 (1993-10-01), None
patent: WO 9422309 (1994-10-01), None
patent: WO 9509913 (1995-04-01), None
patent: WO 9513365 (1995-05-01), None
patent: WO 9531544 (1995-11-01), None
patent: WO 9533051 (1995-12-01), None
patent: WO 9601642 (1996-01-01), None
Black, R. A., et al., 1991, “A metalloprotease disintegrin that releases tumour-necrosis factor-alpha from cells”, Nature, vol. 385, pp. 729-733.*
Moss, M. L, et al., 1991, “Cloning of a distintegrin metalloprotease that processes precursor tumour-necrosis factor-alpha”, Nature, vol. 385, pp. 733-736.*
Peschon, J. J., et al., 1998, “An essential role for ectodomain shedding in mammalian development”, Science, vol. 282, pp. 1281-1284.*
Park, M., et al., 1996, “TNF-receptor releasing enzyme is secreted by PMA-stimulated THP-1 cell line”, The Faseb Journal, vol. 10, No. 6, p. A1484, Abstract No. 2789.*
Gatanaga, T., et al, 1996, TNF-receptor releasing enzynme is secreted by PMA-stimulated THP-1 cell line, The European Cytokine Network, vol. 7, No. 2, p. 166, Abstract No. 14.*
Schlondorff, J., et al., 2001, “Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the Tumor Necrosis Factor convertase”, The Journal of Bioogical Chemistry, vol. 276, pp. 14665-14674.*
Suganama, T., 2001, “Partial amino acid sequences of human TNF receptor releasing enzyme”, Journal of the National Defense Medical College, vol. 26, pp. 11-21.*
Abraham et al., “p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock” (1997)JAMA277:1531-1538.
Aderka et al., “Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients” (1991)Cancer Res. 51:5602-5607.
Aderka et al., “Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors” (1992)J. Exp. Med. 175:323-329.
Aderka et al., “Variation in serum levels of the soluble TNF receptors among healthy individuals” (1992)Lymphokine Cytokine Res. 11:157-159.
Alderson et al., “Regulation of human monocyte cell-surface and soluble CD23 (FCεRII) by granulocyte-macrophage colony-stimulating factor and IL-3” (1992)J. Immunol. 149:1252-1257.
Alexander et al., “Extracellular matrix degradation” (1991)Cell Biology of Extracellular Matrix, ed. Hay, Plenum Press, New York, Chapter 8, pp. 255-302.
Arbós et al., “Effects of tumour necrosis factor-α (cachectin) on glucose metabolism in the rat” (1992)Mol. Cell. Biochem. 112:53-59.
Argilés et al., “The metabolic environment of cancer” (1988)Mol. Cell. Biochem. 81:3-17.
Argilés et al., “Journey from cachexia to obesity by TNF” (1997)FASEB J. 11:743-751.
Armitage,R., “Tumor necrosis factor receptor superfamily members and their ligands” (1994)Curr. Opin. Immunol. 6:407-413.
Ashkenazi et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin” (1991)Proc. Natl. Acad. Sci. USA88:10535-10539.
Baba et al., “Intracarotid infusion of leukotriene C4selectively increased blood-brain barrier permeability after focal ischemia in rats” (1991)J. Cereb. Blood Flow Metab. 11:638-643.
Banner et al., “Crystal structure of the soluble human 55 kd receptor-human TNFβ complex: Implications for TNF receptor activation” (1993)Cell73:431-445.
Baran et al., “Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2” (1988)J. Immunol. 141:539-546.
Bauditz et al., “Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease” (1997)Gut40:470-474.
Baum et al., “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34” (1994)EMBO J. 13:3992-4001.
Beretz et al., “Modulation by cytokines of leukocyte-endothelial cell interactions, implications for thrombosis” (1990)Biorheology27:455-460.
Bermudez et al., “Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor” (1990)Lymphokine Res. 9:137-145.
Beutler et al., “Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin” (1985)Science229:869-871.
Bianchi et al., “Increased Brown adipose tissue activity in children with malignant disease” (1989)Horm. Metab. Res. 21:640-641.
Bickel et al., “Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery” (1993)Proc. Natl. Acad. Sci. USA90:2618-2622.
Birkedal-Hansen et al., “Matrix metalloproteinases: A review” (1993)Crit. Rev. Oral Biol. Med. 4:197-250.
Björnberg et al., “Metalloproteases and serineproteases are involved in the cleavage of the two tumour necrosis factor (TNF) receptors to soluble forms in the myeloid cell lines U-937 and THP-1” (1995)Scand. J. Immunol. 42:418-424.
Bogdan et al., “Macrophage deactivation by interleukin 10” (1991)J. Exp. Med. 174:1549-1555.
Boillot et al., “Myocardial and vascular adrenergic alterations in a rat model of endotoxin shock: Reversal by an anti-tumor necrosis factor-α monoclonal antibody” (1997)Crit. Care Medicine25:540-511.
Bonfil et al., “Invasive and metastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line” (1989)J. Natl. Cancer Inst. 81:587-594.
Brennan et al., “Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy” (1997)Br. J. Rheumatology36:643-650.
Brockhaus et al., “Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies” (1990)Proc. Natl. Acad. Sci. USA87:3127-3131.
Brown, “Matrix metalloproteinase inhibitors: A novel class of anticancer agents” (1995)Advan. Enzyme Regu
Gatanaga Tetsuya
Granger Gale A.
Achutamurthy Ponnathapura
Bozicevic Field & Francis LLP
Francis Carol L.
Moore William W.
The Regents of the University of California
LandOfFree
System for discovering and producing polypeptides that cause... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System for discovering and producing polypeptides that cause..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System for discovering and producing polypeptides that cause... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3491531